Parkinson's Cure Journey

Mitochondria & energy

The lane

Status
Narrowed. Several attempts failed; work continues in a smaller group or with a different drug.
Verdict
CoQ10, creatine, MitoQ and nicotinamide riboside (NOPARK, worse than placebo) all failed; UDCA hit its target; the first USP30 mitophagy drug is in patients.
Family
Housekeeping
Landmarks
27 in this lane, 14 more tagged with it. Advanced 7 · Open 14 · Pending 1 · Superseded 1 · Dead end 4

The verdict and status come from the project's branches.yaml and use research wording.

Landmarks in this lane

27 landmarks drawn in this lane, oldest first. Select a column heading to sort.
Complex I deficiency in the Parkinson's brain1989–1990DiscoveryConfirmed and built on––19 Oct 20263
Parkin mutations cause juvenile parkinsonism1998DiscoveryConfirmed and built on––19 Oct 20262
Rotenone reproduces Parkinson's features in rats2000Research modelConfirmed and built on––19 Oct 20263
Coenzyme Q10 Phase 22002Trial in peopleReplaced by a newer approach28019 Oct 20264
DJ-1 mutations cause early-onset parkinsonism2003DiscoveryStill being studied––19 Oct 20263
PINK1 and the mitophagy pathway2004DiscoveryStill being studied––19 Oct 20264
Mitochondrial DNA deletions in nigral neurons2006DiscoveryStill being studied––19 Oct 20265
PINK1 and parkin share a pathway (flies)2006Research modelConfirmed and built on––19 Oct 20263
MitoPark mouse2007Research modelStill being studied––19 Oct 20261
MitoQ (PROTECT)2010Trial in peopleDid not work212819 Oct 20262
Mitochondrial-derived vesicles2012–2016DiscoveryStill being studied––19 Oct 20263
QE3: coenzyme Q10 fails in Phase 32014Trial in peopleDid not work360019 Oct 20262
NET-PD LS-1: creatine2015Trial in peopleDid not work31,74119 Oct 20262
CHCHD2 (PARK22)2015DiscoveryStill being studied––20 Oct 20264
EPI-589 Phase 2a2016–2019Trial in peopleMixed or early results24419 Oct 20264
Basal mitophagy runs without PINK12018DiscoveryStill being studied––20 Oct 20262
CNM-Au8 (REPAIR-PD)2019–2021Trial in peopleMixed or early results21319 Oct 20264
Terazosin and PGK1 glycolysis2019–2021DiscoveryStill being studied––20 Oct 20263
Terazosin randomised pilot2019–2021Trial in peopleMixed or early results21319 Oct 20262
NOPARK: nicotinamide riboside Phase 32020–2026Trial in peopleDid not work341019 Oct 20263
Complex I loss in dopamine neurons2021Research modelConfirmed and built on––20 Oct 20262
NADPARK Phase 12022Trial in peoplePassed this stage13019 Oct 20262
NR-SAFE: high-dose nicotinamide riboside2022–2023Trial in peoplePassed this stage12019 Oct 20262
UDCA (UP study)2023Trial in peopleMixed or early results23019 Oct 20264
First mitophagy drugs: MTX325, ABBV-10882023–2026Trial in peopleMixed or early results––19 Oct 20264
N-DOSE nicotinamide riboside dose-finding2023–2025Trial in peopleResult due Dec 202628122 Oct 20262
TJ0113 (mitophagy inducer)2024–2028Trial in peopleMixed or early results330019 Oct 20264

Also tagged with this lane

14 landmarks drawn in another lane but tagged with this one. Select a column heading to sort.
MPTP: a chemical that causes Parkinson's1983DiscoveryConfirmed and built on––19 Oct 20264
TCH346 (GAPDH binder)2002–2006Trial in peopleDid not work230119 Oct 20262
POLG mutations cause parkinsonism2004DiscoveryStill being studied––19 Oct 20263
NET-PD futility screens FS-1 and FS-22006–2007Trial in peoplePassed this stage2–19 Oct 20263
PRECEPT: CEP-13472007Trial in peopleDid not work280619 Oct 20263
FBXO7 (PARK15) and PLA2G6 (PARK14)2008–2013DiscoveryConfirmed and built on––19 Oct 20264
PARIS builds up when parkin fails2011DiscoveryStill being studied––19 Oct 20264
The c-Abl idea: mouse studies and a 12-person pilot2014–2015DiscoveryReplaced by a better idea––19 Oct 20262
Pioglitazone (FS-ZONE)2015Trial in peopleDid not work221019 Oct 20263
VPS13C recessive parkinsonism2016DiscoveryStill being studied––20 Oct 20262
Dopamine oxidation damages the lysosome2017DiscoveryStill being studied––20 Oct 20263
Parkin/PINK1–STING paper retracted2018DiscoveryDid not hold up––19 Oct 20262
Gut infection in PINK1-knockout mice2019DiscoveryStill being studied––20 Oct 20263
Risvodetinib (c-Abl), Phase 2 "201"2023–2025Trial in peopleMixed or early results213719 Oct 20265

Built on work from

Led to work in

See this lane on the map · All lanes